VivoSeq
Psychiatry

Suicide

34

Pipeline Programs↗

17

Active Trials↗

18

Companies Involved↗

Suicide is a moderately active landscape with 34 programs across 18 companies. The most active players are Bellicum Pharmaceuticals, Boehringer Ingelheim, Veloxis Pharmaceuticals. 7 therapies are approved with 8 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

56/100

Pipeline Velocity

32/100

Mech. Concentration

28/100

Completion Rate

75/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

B

Bellicum Pharmaceuticals

1 program

Phase 1Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2V

Veloxis Pharmaceuticals

1 program

Phase 2A

Arog Pharmaceuticals, Inc.

1 program

Phase 2C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Phase 2G

Genzyme, a Sanofi Company

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical3

Lithium

Solvay Pharmaceuticals

Suicide Prevention Treatment

Weill Medical College of Cornell University

Lamotrigine 25

GSK

Phase 13

AP1903

Bellicum Pharmaceuticals

Allodepleted T Cells

Baylor College of Medicine

Icaspase9-Transduced T Cells

Baylor College of Medicine

Phase 213

Ketamine Hydrochloride

Boehringer Ingelheim

Midazolam

Conrado Roberto Hoffmann Filho

Tacrolimus

Veloxis Pharmaceuticals

G-CSF

Arog Pharmaceuticals, Inc.

Suvorexant

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 38

Venlafaxine

Wyeth-Lederle Vaccines

Escitalopram

AbbVie

Bupropion

Glaxo Dba Glaxosmithkline

Buprenorphine

Indivior Inc.

Citalopram

AbbVie

Approved7

Estradiol

Novo Nordisk

Ketamine

Aultman Health Foundation

Intravenous Esketamine

University of Sao Paulo

Paroxetine

Sebela Pharmaceuticals Development LLC

Micronized Progesterone

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Analysis

Modality Breakdown

94%

Small molecule

32 of 34 classified programs — the dominant modality here.

6%ALL OTHERSMonoclonal antibody13%Cell therapy13%

Small molecule leads; the ring shows all 34 classified programs, each share of the total. Modality classified for 93% of 41 pipeline programs.

Analysis

Trial Status

40

clinical trials

Completed15 · 38%
Recruiting10 · 25%
Terminated5 · 13%
Unknown status3 · 8%
Active, not recruiting3 · 8%
Not yet recruiting3 · 8%
Other1 · 3%

Clinical Trials

Trial Activity

40 trials

Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial
Recruiting·—·Phase 2·NCT06854224·30 enrolled
iTBS+D-Cycloserine for Youth Suicide
Recruiting·UUniversity of Calgary·Phase 2·NCT06121284·54 enrolled
Ketamine Treatment of Youth Suicide Attempters
Recruiting·—·Phase 3·NCT04763343·60 enrolled
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
Recruiting·MMassachusetts General Hospital·Phase 4·NCT05450432·100 enrolled
A One-Arm Open Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior
Recruiting·MMassachusetts General Hospital·Preclinical·NCT06967545·20 enrolled
An Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
Recruiting·National Institute of Mental Health (NIMH)·Phase 2·NCT06511908·50 enrolled
CA-LINC Randomized Control Trial Study
Recruiting·UUniversity of North Carolina, Chapel Hill·Preclinical·NCT06353711·180 enrolled
Scaling up eConnect in Juvenile Probation Settings: a Hybrid Implementation Effectiveness Trial of a Digital Suicide Risk/Behavior Identification and linkage-to Treatment System
Recruiting·NNew York State Psychiatric Institute·Preclinical·NCT05541926·3,629 enrolled
Esketamine Versus Crisis Response Planning Versus Optimized Treatment as Usual for Suicide Prevention: A Pragmatic Controlled Trial in Two Brazilian Cities
Recruiting·UUniversity of Sao Paulo·Approved·NCT07120477·468 enrolled
Effectiveness and Implementation of a Clinician Decision Support System to Prevent Suicidal Behaviors
Recruiting·MMassachusetts General Hospital·Preclinical·NCT05671133·4,000 enrolled
Opiate Suicide Study in Patients With Major Depression
Active, not recruiting·SStanford University·Phase 3·NCT04116528·60 enrolled
Assisted Suicide in Switzerland
Active, not recruiting·National Institutes of Health Clinical Center (CC)·N/A·NCT04261088·25 enrolled
Efficacy-Implementation Study for Promoting Community Conversations About Research to End Suicide (PC CARES) in Rural Alaska
Active, not recruiting·UUniversity of Michigan·Preclinical·NCT06658808·1,075 enrolled
Caring Texts for Adolescents to Reduce Suicide Risk
Not yet recruiting·AAnn & Robert H Lurie Children's Hospital of Chicago·Preclinical·NCT07043764·56 enrolled
Mentalization and Social Cognition in Adolescents After Suicide Attempt
Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Preclinical·NCT07688798·82 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)